|
Nektar Therapeutics (NASDAQ: NKTR) |
|
Nektar Therapeutics
NKTR's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Nektar Therapeutics's sales fell
by -51.66 % in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.5 %
Nektar Therapeutics net loss increased from $-37 millions, to $-51 millions in first quarter of 2025,
• More on NKTR's Growth
|
|
Nektar Therapeutics realized a net loss in trailing twelve months.
Nektar Therapeutics realized cash reduction of $ -0.05 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
• More on NKTR's Valuation
|
|
|
|
|
Nektar Therapeutics realized net loss in trailing twelve months.
Nektar Therapeutics realized cash outflow of $ -0.05per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 1.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
Nektar Therapeutics Price to Book Ratio is at 10.52 lower than Industry Avg. of 33.19. and higher than S&P 500 Avg. of 0.01
• More on NKTR's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com